• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Wednesday 12/12/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

WRTC

  • 1:26 PM

    Retired Police Chief and Professor at Loyola University is Recognized Expert in Community Policing and Use of Force LAS VEGAS, NV / ACCESSWIRE / September 5, 2018 / Wrap Technologies, Inc. (the ”Company”) (OTCQB: WRTC), an innovator of modern policing solutions, announced today that Professor Ronal Serpas, Ph.D. will be advising the Company and its law enforcement customers on integrating the new BolaWrap 100 with effective community policing. It is well recognized by the field of professional law enforcement leaders and

    Read more
  • 11:53 AM

    LAS VEGAS, NV / ACCESSWIRE / July 10, 2018 / Wrap Technologies, Inc. (OTCQB: WRTC), an innovator of modern policing solutions, today announced the granting of its first U.S. patent and recapped its intellectual property strategy. The Company recently secured its first U.S. patent on its BolaWrap remote restraint technology and has an additional seven U.S. patents pending. The Company has also filed to reserve all international patent rights to its BolaWrap innovations. The Company’s strategy is to protect and vigorously

    Read more
  • 3:15 PM

    VANCOUVER, Wash., Dec. 14, 2015, CYDY, (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that it has been cleared by the FDA to conduct a Phase 2 trial for Graft versus Host Disease (GvHD), which is a life-threatening complication for patients undergoing stem cell transplants. CytoDyn currently is conducting a Phase 3 pivotal trial with its lead product candidate, PRO 140, for the

    Read more
  • 12:49 PM

    VANCOUVER, Wash., Oct. 22, 2015, OTCQB, CYDY, (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that the first patient in its Phase 3 clinical trial has been injected with PRO 140, the Company’s monoclonal antibody for the treatment of HIV. PRO 140 is the first self-injectable antibody in a Phase 3 protocol involving 300 HIV patients that will each be evaluated over a

    Read more
  • 2:00 PM

    CytoDyn (PublicWire) — CytoDyn, Inc. (Pink Sheets:CYDY) has agreed to provide an additional $204,000 for the current clinical trial of Cytolin®, the Company’s novel immune therapy for treating HIV/AIDS. This will enable the Principal Investigator to hire additional personnel in order to ensure that key data from the study will be available by December 31, 2010. For details about the clinical trial visit http://clinicaltrials.gov. and enter Cytolin as a search term.

    Read more
Public Wire Banner